Cite
MLA Citation
Johann Bartko et al.. “A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.” Clinical pharmacology & therapeutics, vol. 104, no. 4, 2018, pp. 655–663. http://access.bl.uk/ark:/81055/vdc_100069103479.0x000059